Outcome of pediatric patients with acute lymphoblastic leukemia/lymphoblastic lymphoma with hypersensitivity to pegaspargase treated with PEGylated Erwinia asparaginase, pegcrisantaspase: A report from the Children's Oncology Group

BACKGROUND: Erwinia asparaginase is a Food and Drug Administration approved agent for the treatment of acute lymphoblastic leukemia (ALL) for patients who develop hypersensitivity to Escherichia coli derived asparaginases. Erwinia asparaginase is efficacious, but has a short half-life, requiring six...

पूर्ण विवरण

में बचाया:
ग्रंथसूची विवरण
में प्रकाशित:Pediatr Blood Cancer
मुख्य लेखकों: Rau, Rachel E., Dreyer, ZoAnn, Choi, Mi Rim, Liang, Wei, Skowronski, Roman, Allamneni, Krishna P., Devidas, Meenakshi, Raetz, Elizabeth A., Adamson, Peter C., Blaney, Susan M., Loh, Mignon L, Hunger, Stephen P.
स्वरूप: Artigo
भाषा:Inglês
प्रकाशित: 2017
विषय:
Article
ऑनलाइन पहुंच:https://ncbi.nlm.nih.gov/pmc/articles/PMC5839116/
https://ncbi.nlm.nih.gov/pubmed/29090524
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/pbc.26873
टैग : टैग जोड़ें
कोई टैग नहीं, इस रिकॉर्ड को टैग करने वाले पहले व्यक्ति बनें!

समान संसाधन